Atacana Group > Resources Center > Reports > Pharma Daily Digest
Dark Mode

Pharma Daily Digest

05/31/2024
05/31/2024
Atacana Group
Author


Your Daily Dose of Pharma News

Welcome to the Daily Pharma Digest, your go-to source for the latest updates in the pharmaceutical industry. Whether you’re a professional in the field, an investor, or simply passionate about healthcare innovations, our digest provides you with concise and impactful news to keep you informed.


Today’s Highlights (May 31, 2024: Winners & Losers) 👇

😃 **Winners**

  • Bristol Myers Squibb Myers: secures another FDA go-ahead for Breyanzi, this time in mantle cell lymphoma
  • AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
  • Sanofi Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
  • Candel Therapeutics: Received FDA Orphan Drug Designation for CAN-3110 for recurrent high-grade glioma treatment.
  • Soterios Pharma sees phase 2 win for alopecia cream as offering alternative to JAK domination
  • SN Bioscience, following the FDA, EMA also Grants an Orphan Drug Designation to Nano Anti-Cancer Drug ‘SNB-101’ for Small Cell Lung Cancer.
  • Ori Biotech: Unveiled an automated cell therapy production platform, boosting manufacturing capabilities.
  • Cytiva: Launched a new CAR-T manufacturing platform, developed with @Kite for improved cell therapy production.
  • Cyclo Therapeutics, Inc.: Completed enrollment of the last patient in phase 3 TransportNPC trial for Niemann-Pick Disease Type C1 treatment.
  • Syncromune®, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer
  • Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  • Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001, a potentially disease-modifying treatment for fronto-temporal dementia
  • InxMed 应世生物 Reports Positive Phase Ib/II Results for Ifebemtinib in Combination with Garsorasib in Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
  • Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria


😔 **Losers**

  • Gilead Sciences’s Trodelvy suffers double whammy as failed bladder cancer trial raises flag over early deaths


What are your thoughts on these developments? Who will be the next winner or loser?



Be in the Know

Sign up for our newsletter and never miss an update on the movers and shakers in the pharma world. Get exclusive insights, in-depth analyses, and predictions on who will be the next winner or loser in the industry.

Pharma Daily Digest

Name*(Required)

By signing up, you agree to receive emails from Daily Pharma Digest and agree to our Privacy Policy.